Figure 6 | Scientific Reports

Figure 6

From: Systems assessment of intercalated combination of chemotherapy and EGFR TKIs versus chemotherapy or EGFR TKIs alone in advanced NSCLC patients

Figure 6

Subgroup analysis of EGFR genotype.

(A) PFS and OS of chemotherapy plus interval EGFR TKIs vs. EGFR TKI monotherapy for the NSCLC patients with EGFR gene wild type; (B) PFS of chemotherapy plus interval EGFR TKIs vs. chemotherapy alone for the NSCLC patients with EGFR gene wild type; (C) PFS of chemotherapy plus interval EGFR TKIs vs. chemotherapy for the NSCLC patients with EGFR mutations; (D) OS of chemotherapy plus interval EGFR TKIs vs. chemotherapy for the NSCLC patients with EGFR mutations.

Back to article page